{"id":3074,"date":"2024-05-02T11:45:45","date_gmt":"2024-05-02T11:45:45","guid":{"rendered":"https:\/\/wagner-lab.de\/?page_id=3074"},"modified":"2024-10-28T11:36:29","modified_gmt":"2024-10-28T11:36:29","slug":"projects-new","status":"publish","type":"page","link":"https:\/\/wagner-lab.de\/?page_id=3074","title":{"rendered":"Projects new"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"3074\" class=\"elementor elementor-3074\" data-elementor-post-type=\"page\">\n\t\t\t\t<div class=\"elementor-element elementor-element-6d7b4122 e-flex e-con-boxed e-con e-parent\" data-id=\"6d7b4122\" data-element_type=\"container\" id=\"hiv\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-31e3b459 e-con-full e-flex e-con e-child\" data-id=\"31e3b459\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-411827a7 elementor-widget elementor-widget-heading\" data-id=\"411827a7\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">HIVacToGC<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-51e16fff elementor-widget elementor-widget-text-editor\" data-id=\"51e16fff\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p class=\"bodytext\"><b>Funding: The Federal Ministry of Education and Research (BMBF)\nTitle: HI<\/b>V <strong>Vac<\/strong>cine <strong>T<\/strong>argeting via DNA <strong>O<\/strong>rigami Nanoparticles to lymph nodes to promote <strong>G<\/strong>erminal <strong>C<\/strong>enter formation<\/p>\n<p class=\"bodytext\">HIV has so far defied all attempts to develop an effective vaccine against it. Nine efficacy trials testing several vaccine candidates have been conducted in the last 25 years, with only one of them resulting in very modest, insufficient protection. One trial, PrEPVacc, is still ongoing.<\/p>\n\n<div class=\"container\"><span class=\"moreText\">\nYet, in the 40 years since HIV\u2019s discovery, a lot has been learned about the virus, the reaction of the human immune system, and the means how HIV escapes the immune response.\n\n<\/span>\n<button class=\"readMoreBtn\">Read more<\/button><\/div>\n<strong>Project partners:<\/strong>\nMolecular Microbiology (Virology), Institute of Medical Microbiology and Hygiene, University of Regensburg \u2013 Project co-ordinator,\nPharmaceutical Technology, University of Regensburg,\nTechnical University of Munich (TUM),\nHelmholtz Zentrum M\u00fcnchen,\nTilibit nanosystems GmbH,\n2bind GmbH\n\n<!-- Add other project partners here -->\n\n<b>Further information:<\/b>\n<a class=\"external-link-new-window\" title=\"Opens external link in new window\" href=\"https:\/\/hivactogc.com\/\" target=\"_blank\" rel=\"noopener\">HIVacToGC Project site<\/a>\n<a href=\"https:\/\/wagner-lab.de\/?p=102\">Pressemitteilung<\/a>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-62b5023d e-con-full e-flex e-con e-child\" data-id=\"62b5023d\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2ab5f8d5 elementor-widget elementor-widget-image\" data-id=\"2ab5f8d5\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"600\" height=\"172\" src=\"https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/01\/cropped-hivactogc4.gif\" class=\"attachment-large size-large wp-image-1502\" alt=\"\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-724a4a9f e-flex e-con-boxed e-con e-parent\" data-id=\"724a4a9f\" data-element_type=\"container\" id=\"nano\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-75f0c577 e-con-full e-flex e-con e-child\" data-id=\"75f0c577\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-4bfd0e13 elementor-widget elementor-widget-heading\" data-id=\"4bfd0e13\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">NanoNeutVir\n<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-ad68090 elementor-widget elementor-widget-text-editor\" data-id=\"ad68090\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p class=\"bodytext\"><strong>Funding: Bundesministerium f\u00fcr Bildung und Forschung (BMBF)<\/strong><\/p>\nNeutralizing antibodies provide suitable protection against either infection with SARS-CoV-2 virus or at least protection against severe illness e.g. corona virus induced disease 19 (COVID19) and death.\n\nTo achieve the desired project aims, different competences are required. Therefore, the project brings together experts from the fields of analytical chemistry, molecular immunology, and virology collaboration with biotech industry to generate a product ready to enter the market. Moreover, this platform can be used in the future to provide a chassis for test assays to detected potent immunity against new emerging virus that might come.\n<div class=\"container\"><span class=\"moreText\">\nWithin the NanoNeutVir consortium, the Wagner Lab is involved in the evolution of those components that provide the liposomes specificity, especially to provide recombinant proteins of RBD variants and ACE2. Moreover, the team will test the efficacy of the established assay with qualified patient sera and benchmark the liposome-based assay against conventional neutralization assays.\n<\/span>\n<button class=\"readMoreBtn\">Read more<\/button><\/div>\n<strong>Project partners:\n<\/strong>University of Regensburg, Institute for Analytical Chemistry \u2013 project coordinator\nUniversity of Regensburg, Institute for Medical Microbiology and Hygiene, Molecular Microbiology (Virology)\nUniversity of Marburg\nMicrocoat Biotechnology GmbH, Bernried\n\n\n<strong>Further information:<\/strong>\n<a href=\"https:\/\/www.microcoat.de\/\">https:\/\/www.microcoat.de<\/a>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-653f3cff e-con-full e-flex e-con e-child\" data-id=\"653f3cff\" data-element_type=\"container\">\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-68a0a25c e-flex e-con-boxed e-con e-parent\" data-id=\"68a0a25c\" data-element_type=\"container\" id=\"ehva\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-6af60be0 e-con-full e-flex e-con e-child\" data-id=\"6af60be0\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-5b5e501 elementor-widget elementor-widget-heading\" data-id=\"5b5e501\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">EHVA<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-7ffe9857 elementor-widget elementor-widget-text-editor\" data-id=\"7ffe9857\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p class=\"bodytext\"><span style=\"font-weight: bolder;\">Funding:<\/span>\u00a0<span style=\"font-weight: bolder;\">European Union\u2019s Horizon 2020 Research and Innovation Programme<\/span><\/p>\n<span style=\"font-weight: bolder;\">The European HIV Vaccine Alliance (EHVA)<\/span>\u00a0\u2013 funded by the European Union\u2019s H2020 Program \u2013 aims at discovering and evaluating new prophylactic and therapeutic HIV-1 vaccine candidates. The program is coordinated by Prof. Yves L\u00e9vy (INSERM, Paris) and Prof. Giuseppe Pantaleo (CHUV, Lausanne) and comprises\u00a0<span style=\"font-weight: bolder;\">39 partners from 15 countries<\/span>.\n\nWithin the alliance, the University of Regensburg coordinates the Vaccine-Discovery- Workpackage for novel antigen candidates, delivery systems and formulations.<br>\n\n<div class=\"container\"><span class=\"moreText\">\n\nThe antigens will be based on HIV\u2019s envelope protein (Env, see picture) that is the target for protective antibody responses. A novel generation of Env-variants characterized by improved trimer-stability, immuno-focussing towards target sites of broadly neutralizing antibodies, and immuno-silencing of non-neutralizing sites will be generated by rational design and evolutionary approaches (e.g. selection from libraries of Env-variants). The generated variants will be compared with the best Env-antigen currently available (BG505.SOSIP) by means of biochemical, biophysical and immunological tests.<br>\n\nMoreover, novel delivery systems, including new types of virus-like particles (VLPs), and formulations will be assessed for their modulatory capacity on the strength, breadth and quality of the immune responses elicited by the novel Env antigens.\nIn addition, our team will develop a framework to design novel DNA-vaccine vectors that elicit high-quality immune responses matching pre-defined criteria that can, for instance, be derived from the knowledge about correlates of protection. The new DNA vectors, as well as novel approaches based on RNA delivery, novel poxviruses or VSV-based viruses will be benchmarked against the PTVDC-DNA-vaccine that has previously been developed and clinically tested by our group.\n\nThe best-in-class antigens and delivery systems will then be assessed in non-human primate studies for safety and immunogenicity to identify the candidates that will be furthered into clinical development.\n\nFinally, our team also closely cooperates with the partners in the immune profiling platform, the data management \/ integration \/ down-selection platform, and the clinical trials platform.\n\n<\/span>\n<button class=\"readMoreBtn\">Read more<\/button><\/div>\n\n<span style=\"font-weight: bolder;\">Further information:\n<\/span>Project website:\u00a0<a href=\"http:\/\/www.ehv-a.eu\/\">http:\/\/www.ehv-a.eu\/<\/a>\nFactSheet:\u00a0<a href=\"http:\/\/www.ehv-a.eu\/EHVApdf.pdf\">http:\/\/www.ehv-a.eu\/EHVApdf.pdf<\/a>\nEC project webpage:\u00a0<a href=\"http:\/\/ec.europa.eu\/programmes\/horizon2020\/en\/news\/european-alliance-accelerate-new-concepts-hiv-vaccine-research\">http:\/\/ec.europa.eu\/programmes\/horizon2020\/en\/news\/european-alliance-accelerate-new-concepts-hiv-vaccine-research<\/a>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-7ec580f0 e-con-full e-flex e-con e-child\" data-id=\"7ec580f0\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-1d413291 elementor-widget elementor-widget-image\" data-id=\"1d413291\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"300\" height=\"164\" src=\"https:\/\/wagner-lab.de\/wp-content\/uploads\/2023\/10\/1.png\" class=\"attachment-large size-large wp-image-334\" alt=\"\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-160dd132 elementor-widget elementor-widget-image\" data-id=\"160dd132\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"400\" height=\"305\" src=\"https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/02\/EHVA2.png\" class=\"attachment-large size-large wp-image-2318\" alt=\"\" srcset=\"https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/02\/EHVA2.png 400w, https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/02\/EHVA2-300x229.png 300w\" sizes=\"(max-width: 400px) 100vw, 400px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5584a625 elementor-widget elementor-widget-image\" data-id=\"5584a625\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"250\" height=\"232\" src=\"https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/02\/8bd4f6d401.png\" class=\"attachment-large size-large wp-image-2370\" alt=\"\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-5569d1fb e-flex e-con-boxed e-con e-parent\" data-id=\"5569d1fb\" data-element_type=\"container\" id=\"hfv\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-6d2eee93 e-con-full e-flex e-con e-child\" data-id=\"6d2eee93\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-4b7e9560 elementor-widget elementor-widget-heading\" data-id=\"4b7e9560\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">HFVac3<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-519aa95a elementor-widget elementor-widget-text-editor\" data-id=\"519aa95a\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p class=\"bodytext\"><strong>Funding: Innovate UK<\/strong>\n<strong>Title:<\/strong>\u00a0<strong>Clinical trial of a DIOS Trivalent Haemorrhagic Fever Vaccine<\/strong><\/p>\n\nThe HFVac3-project is based on the predecessor projects EVAC and Tri-LEMvac that also were funded by Innovate UK. Within the EVAC project, a streamlined process for vaccine generation starting with in silico design of antigen sequences, over the generation of delivery vectors (DNA, adenovirus, vaccinia virus) and rapid testing for immunogenicity in small animal models (mice and guinea pigs) \u2013 all steps to be completed within one year \u2013 had been developed.<br>\n\n<div class=\"container\"><span class=\"moreText\">\n\nIn a parallel track within the Tri-LEMvac project, proof-of-concept for immunogenicity and (in part) efficacy of such vaccine candidates against three different haemorrhagic fever viruses (Lassa, Ebola, and Marburg virus) has been obtained. Now, the outcomes of these two projects will be joined to come up with a clinical vaccine candidate and start a phase I clinical trial to assess the safety and immunogenicity of this vaccine candidate addressing the three viral diseases.<\/span><\/span>The Wagner lab contribution to the project encompasses the generation and characterization of the MVA vaccine candidate vector suitable for GMP manufacturing.\n<\/span>\n<button class=\"readMoreBtn\">Read more<\/button>\n<\/div>\n\n<strong>Project partners:<\/strong>\nProf. Jonathan Heeney (University of Cambridge) \u2013 project co-ordinator,\nProf. Ralf Wagner (University of Regensburg, Institute for Medical Microbiology and Hygiene, Molecular Microbiology (Virology),\nDIOSynVax Ltd.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-5ffcf7b4 e-con-full e-flex e-con e-child\" data-id=\"5ffcf7b4\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-77b06eed elementor-widget elementor-widget-image\" data-id=\"77b06eed\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"600\" height=\"159\" src=\"https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/02\/1.png\" class=\"attachment-large size-large wp-image-2323\" alt=\"\" srcset=\"https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/02\/1.png 600w, https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/02\/1-300x80.png 300w\" sizes=\"(max-width: 600px) 100vw, 600px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-5329fc70 e-flex e-con-boxed e-con e-parent\" data-id=\"5329fc70\" data-element_type=\"container\" id=\"mr\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-22b0a8a3 e-con-full e-flex e-con e-child\" data-id=\"22b0a8a3\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-5745ce0d elementor-widget elementor-widget-heading\" data-id=\"5745ce0d\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">MR-BioQuant<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1ccfe29b elementor-widget elementor-widget-text-editor\" data-id=\"1ccfe29b\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<b>Funding: BMBF VIP+\nFull title: Ultrasensitive Magnetresonanz f\u00fcr die in vitro Biomarkerquantifizierung in Diagnostik und Therapie<\/b>\n\nDisease-related proteins and cells play a major role in biomedical research and clinical care. Although the quantitative detection of these biomarkers is becoming increasingly important, there are deficits due to the large variability and the low comparability of the results. The BMBF-funded project MR-BioQuant is intended to set the stage for the use of an innovative technology for precise and reproducible biomarker quantification with a sensitivity in the nanomolar concentration range.\n<div class=\"container\">\n    <span class=\"moreText\">\nThe physical basis of the technology is the reversible binding of hyperpolarized xenon to a sensor biomolecule that recognizes the biomarker of interest, but can also be detected indirectly via the xenon NMR signal with a so-called saturation transfer. The particular potential of this measurement method developed at PTB (Physikalisch-Technische Bundesanstalt) is that it can deliver correct results on biological samples irrespective of variations in the sample composition or change of the measurement platform.\n\nExemplary biosensors are to be generated by enabling antibodies to bind xenon. With the help of these sensor molecules, selected biomarkers should be quantified using the BioQuant method. The potential superiority of the approach is to be validated by benchmarking with conventional methods. The method\u2019s high innovative potential, especially for biomedical research tasks, will be demonstrated in applications from vaccine development.\n\nThese application examples, together with the implementation of the measurement method on different device platforms, should form the basis for an economic utilization of the BioQuant method by life science research companies and NMR device manufacturers.\n\nWithin the MR-BioQuant project, the Wagner Lab is responsible for the generation of suitable biosensor molecules derived from different viruses (recombinant viral proteins) or antibodies targeting viral proteins that enable the validation of the BioQuant method.\n<\/span>\n<button class=\"readMoreBtn\">Read more<\/button>\n<\/div>\n<b>Project partners:<\/b>\nPhysikalisch-Technische Bundesanstalt Braunschweig und Berlin (PTB) \u2013 Coordinator\nUniversit\u00e4t Regensburg, Institut f\u00fcr Mikrobiologie und Hygiene, Molekulare Mikrobiologie (Virologie) (UR-MED)\nUniversit\u00e4t Regensburg, Institut f\u00fcr Biophysik und Physikalische Biochemie (UR-BIO)\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-38065219 e-con-full e-flex e-con e-child\" data-id=\"38065219\" data-element_type=\"container\">\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-31c0eb e-flex e-con-boxed e-con e-parent\" data-id=\"31c0eb\" data-element_type=\"container\" id=\"viro\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-511c5344 e-con-full e-flex e-con e-child\" data-id=\"511c5344\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-54097500 elementor-widget elementor-widget-heading\" data-id=\"54097500\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">VIROFIGHT<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-635a6dd elementor-widget elementor-widget-text-editor\" data-id=\"635a6dd\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p class=\"bodytext\"><b>Funding: EU \u2013 Horizon 2020<br \/>Full title: European Consortium for the Development of Novel Therapies against Viruses such as SARS-CoV-2, HIV, Influenza or Hepatitis<\/b><\/p><p>Current antiviral drugs constitute small molecules that target and inactivate typical proteins or enzymes of selected viruses. Within the EU-funded Virofight project (coordinated by the Technical University of Munich), nanometer sized shells shall be developed that enclose viruses, thus neutralizing them. This new approach might allow targeting of diverse viruses by employing the same method.<\/p><div class=\"container\"><span class=\"moreText\"><span class=\"moreText\"><br \/>Virus infections affect millions of people each year. They cause severe human suffering and enormous costs to society. The current COVID-19 pandemic is only one of many examples. For more than 70 % of viruses listed by the WHO, no therapy is available, and the existing antiviral drugs have to be administered very shortly after infection to be effective. The Virofight consortium proposes a new approach to fight virus infections that shall make it possible to counter the shortage of broadly applicable antivirals and also to target newly emerging pathogens.<\/span><\/span><p>The aim is to develop prototypes of nano-shells and to principally prove that they are capable of enclosing different viruses. Different technologies will be applied during the development of these biocompatible nano-shells such as DNA origami, protein design and in-vitro-evolution. The interior of the shells will be coated with molecules that are tuned to certain viruses and ensure a strong and specific interaction. These binding effects shall be assessed for different viruses on a laboratory scale. To achieve the desired project aims, different competences are required. Therefore, the project brings together experts from the fields of supermolecular chemistry, molecular nano-engineering and virology.<\/p><p>Within the Virofight consortium, the Wagner Lab is involved in the evolution of those components that provide the nano-shells with specificity toward the different viruses. Moreover, the team will test the efficacy of the nano-shell protoypes against HIV, influenza or corona viruses.<\/p><button class=\"readMoreBtn\">Read more<\/button><\/div><p><strong>Project partners:<\/strong><br \/>Technical University Munich (TUM; Germany) \u2013 project coordinator<br \/>Molecular Microbiology (Virology), Institute of Medical Microbiology and Hygiene, University of Regensburg (Germany)<br \/>Aarhus University (Denmark)<br \/>ARTTIC S.A.S. (France)<br \/>National Institute of Chemistry (Slovenia)<\/p><p><b>Further information:<\/b><br \/><a class=\"external-link-new-window\" href=\"https:\/\/www.virofight.eu\/\" target=\"_blank\" rel=\"noopener\">Virofight Website<\/a><br \/><a class=\"external-link-new-window\" href=\"https:\/\/cordis.europa.eu\/project\/id\/899619\/de\" target=\"_blank\" rel=\"noopener\">EU Cordis portal<br \/><\/a><a href=\"https:\/\/wagner-lab.de\/?p=115\">Our press release on VIROFIGHT project<\/a><br \/><strong><a href=\"https:\/\/wagner-lab.de\/?p=3600\">Press release on the hybrid VIROFIGHT Symposium on &#8220;Antiviral Biologics&#8221; on Friday, 22nd November 2024 in Garching, Germany<\/a><\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-272d2cfb e-con-full e-flex e-con e-child\" data-id=\"272d2cfb\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-6abd102a elementor-widget elementor-widget-image\" data-id=\"6abd102a\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"310\" height=\"120\" src=\"https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/02\/1-1.png\" class=\"attachment-large size-large wp-image-2331\" alt=\"\" srcset=\"https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/02\/1-1.png 310w, https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/02\/1-1-300x116.png 300w\" sizes=\"(max-width: 310px) 100vw, 310px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-f46f3b elementor-widget elementor-widget-image\" data-id=\"f46f3b\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"375\" height=\"375\" src=\"https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/02\/1-s2.0-S266638642200563X-fx1.png\" class=\"attachment-large size-large wp-image-2330\" alt=\"\" srcset=\"https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/02\/1-s2.0-S266638642200563X-fx1.png 375w, https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/02\/1-s2.0-S266638642200563X-fx1-300x300.png 300w, https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/02\/1-s2.0-S266638642200563X-fx1-150x150.png 150w\" sizes=\"(max-width: 375px) 100vw, 375px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-115f1045 elementor-widget elementor-widget-text-editor\" data-id=\"115f1045\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p class=\"bodytext\">Assembly and functionalization schematic of DNA-Origami nanoshells as published in Monferrer et al, Science physical reports, 2023 https:\/\/doi.org\/10.1016\/j.xcrp.2022.101237<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-2a5070a9 e-flex e-con-boxed e-con e-parent\" data-id=\"2a5070a9\" data-element_type=\"container\" id=\"treat\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-5e69f6dc e-con-full e-flex e-con e-child\" data-id=\"5e69f6dc\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-443b4927 elementor-widget elementor-widget-heading\" data-id=\"443b4927\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">TREATCANCERV<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-327a80d8 elementor-widget elementor-widget-text-editor\" data-id=\"327a80d8\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p class=\"bodytext\"><b>Funding:<\/b>\u00a0<b>Eurostars<\/b>\n<strong>Full title: Treating cancer by targeting endogenous retroviral fossils within the human genome<\/strong><\/p>\nHuman endogenous retroviruses (HERVs) are transposable retroviral elements accounting for about 8 % of the human genome. They are ancient relicts acquired through multiple infections of the germ line by now extinct exogenous retroviruses.\n<div class=\"container\">\n    <span class=\"moreText\">\nAlthough many HERV sequences have acquired inactivating mutations during human evolution, some HERVs retain protein-coding functions, which partly play important roles in human physiology and pathology. For example, correlation between HERVs and human cancer has been described for melanoma, breast cancer, germ cell tumours, renal cancer and ovarian cancer where HERV Envelope (Env) proteins are overexpressed compared to healthy tissues.\n\nThe TREATCANCERV partners therefore aim at developing therapeutic vaccines as well as therapeutic monoclonal antibodies (mAbs) targeting these HERV Env proteins.\n\nThe Wagner lab contributes to this project by designing antigens based on the Env protein for different HERV strains, which will then be used for the production of hybridoma cell lines expressing monoclonal antibodies targeting these antigens. The project partner Sirion-Biotech will produce adenoviral vectors carrying the same antigens while our project partners from the University of Copenhagen and the Danish company InProTher will develop the therapeutic vaccination approach based on a Virus-Like-Vaccine (VLV).\n<\/span>\n<button class=\"readMoreBtn\">Read more<\/button>\n<\/div>\n<b>Project partners:<\/b>\nHervolution ApS (Copenhagen, Denmark)\nMolecular Microbiology (Virology), Institute of Medical Microbiology and Hygiene, University of Regensburg (Germany)\nUniversity of Copenhagen (Copenhagen, Denmark)\nSirion-Biotech (Munich, Germany)\n\n<b>Further information:<\/b>\n<a href=\"https:\/\/hervolutiontx.com\/\">https:\/\/hervolutiontx.com<\/a><a class=\"external-link-new-window\" title=\"Opens external link in new window\" href=\"https:\/\/research.ku.dk\/\" target=\"_blank\" rel=\"noopener\">\n<\/a><a class=\"external-link-new-window\" title=\"Opens external link in new window\" href=\"https:\/\/sirion-biotech.com\/\" target=\"_blank\" rel=\"noopener\">https:\/\/www.sirion-biotech.com\/<\/a>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-39d8df7c e-con-full e-flex e-con e-child\" data-id=\"39d8df7c\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-492f627e elementor-widget elementor-widget-image\" data-id=\"492f627e\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"800\" height=\"228\" src=\"https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/02\/Bild1-no-bg-1024x292.png\" class=\"attachment-large size-large wp-image-2249\" alt=\"\" srcset=\"https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/02\/Bild1-no-bg-1024x292.png 1024w, https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/02\/Bild1-no-bg-300x86.png 300w, https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/02\/Bild1-no-bg-768x219.png 768w, https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/02\/Bild1-no-bg.png 1268w\" sizes=\"(max-width: 800px) 100vw, 800px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-3e9b8bd7 e-flex e-con-boxed e-con e-parent\" data-id=\"3e9b8bd7\" data-element_type=\"container\" id=\"deep\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-1dd186d8 e-con-full e-flex e-con e-child\" data-id=\"1dd186d8\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-3b90b4cd elementor-widget elementor-widget-heading\" data-id=\"3b90b4cd\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">DeeP-CMV<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3376f15d elementor-widget elementor-widget-text-editor\" data-id=\"3376f15d\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<strong>Funding: EU \u2013 Horizon 2020<\/strong>\n<strong>Full title: Diagnostic, therapy and prevention before cytomegaloviral infection<\/strong>\n\nThe human cytomegalovirus (CMV) is one of the most important pathogens in humans and triggers as an opportunistic pathogen in certain high-risk situations, e.g. under drug-induced immunosuppression, after bone marrow or organ transplantation and during pregnancy, it causes severe, sometimes life-threatening infections. CMV infection is the most common infection-related risk for neonatal defects today. Currently, there is no vaccine available and decades of experience with anti-herpesviral therapies have not been able to solve the problems of low tolerability and viral resistance.\n<div class=\"container\">\n    <span class=\"moreText\">\nThe established, reliable diagnostics (genome PCR detection, antigenemia test, and serology) are limited in that they are not predictive of viral load and about the CMV-associated pathogenesis. This limitation is particularly relevant to the major problem of CMV infection during pregnancy about viral transmission to the unborn child and the likelihood of a pathogenic course. In addition, there is an urgent medical need for improved CMV treatment strategies, pharmacologic prophylaxis and test strategies.\n\nThe cooperating partners are aiming a targeted knowledge gain in diagnostic, therapy and prevention. Therefore, antibody signatures are a target for CMV disease and transmission prediction. Serological and molecular test strategies can improve the early diagnosis and specification of viral load. Specific CDK-inhibitors are designed for a selective inhibition of viral CDK-dependent processes. Finally, for the prevention before infection, the development of a vaccine is in focus.\n\nWithin the DeeP-CMV project, the Wagner Lab of the University of Regensburg develops in cooperation with Sirion Biotech different adenoviral, MVA and mRNA based vectors. Development shall comprise various antigen designs addressing induction of T- and B-cell responses as well as various vector optimizations. Newly generated vectors are characterized in in vitro and in vivo models.\n\nIn addition, the development of a RT-qPCR based test is supported for a more detailed and efficient testing compared to conventional methods. The higher sensitivity of RT-qPCR compared to the conventional ELISpot would also make it possible to test new-borns.\n<\/span><button class=\"readMoreBtn\">Read more<\/button>\n<\/div>\n\n<strong>Project partners:<\/strong>\nFriedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU, Germany) \u2013 project coordinator\nMolecular Microbiology (Virology), Institute of Medical Microbiology and Hygiene, University of Regensburg (Germany)\nVirion\/Serion (W\u00fcrzburg, Germany)\nMikrogen GmbH (Germany)\nSirion Biotech GmbH (Germany)\nLead Discovery Center (LDC, Germany)\n\n<strong>Further information:<\/strong>\n<a href=\"https:\/\/forschungsstiftung.de\/Projekte\/Details\/DeeP-CMV-Diagnostik-Therapie-und-Pravention-der-Cytomegalovirus-Infektion.html\">Bavarian Research Foundation<\/a>\n<a href=\"https:\/\/sirion-biotech.com\/\">Sirion Biotech GmbH<\/a>\n<a href=\"https:\/\/www.uni-wh.de\/gesundheit\/department-fuer-humanmedizin\/lehrstuehle-institute-und-zentren\/lehrstuhl-fuer-virologie-und-mikrobiologie\/\">University Witten\/Herdecke<\/a>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-665ac83e e-con-full e-flex e-con e-child\" data-id=\"665ac83e\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-2f3b9f03 elementor-widget elementor-widget-image\" data-id=\"2f3b9f03\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"499\" height=\"263\" src=\"https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/02\/Bild1-1.png\" class=\"attachment-large size-large wp-image-2387\" alt=\"\" srcset=\"https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/02\/Bild1-1.png 499w, https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/02\/Bild1-1-300x158.png 300w\" sizes=\"(max-width: 499px) 100vw, 499px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-75950706 elementor-widget elementor-widget-image\" data-id=\"75950706\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"719\" height=\"461\" src=\"https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/02\/3-1.png\" class=\"attachment-large size-large wp-image-2345\" alt=\"\" srcset=\"https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/02\/3-1.png 719w, https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/02\/3-1-300x192.png 300w\" sizes=\"(max-width: 719px) 100vw, 719px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-4f14551 e-flex e-con-boxed e-con e-parent\" data-id=\"4f14551\" data-element_type=\"container\" id=\"sars\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-9eae3a0 e-con-full e-flex e-con e-child\" data-id=\"9eae3a0\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-37e7909f elementor-widget elementor-widget-heading\" data-id=\"37e7909f\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Inhibiting SARS-CoV-2 N-Protein-Mediated Infectivity<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6f1e9b58 elementor-widget elementor-widget-text-editor\" data-id=\"6f1e9b58\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tThe aim of this project is to identify active substances that specifically prevent the packaging of the SARS-CoV-2 genome into the viral particle and thus inhibiting its replication. Packaging of the viral genome into the virus is an essential process in the viral life cycle whereby the nucleocapsid protein (N) specifically binds to the RNA genome and organizes its packaging in the virus. In particular, SARS N undergoes liquid-liquid phase separation (LLPS) with RNA, which contributes to viral transcription, replication and ultimately virion assembly.\n<div class=\"container\">\n    <span class=\"moreText\">\nIn this project, a structure- based and cellular screening system will be established that can identify molecules that interact with N. Moreover, the functional effects of these interactors on RNA-binding and packaging will be analysed. Ultimately, to determine effective therapeutics, their impact on viral replication and infectivity will be directly assessed in cellular systems. For this we already successfully established a stable cell line that can be induced by doxocycline to express SARS-CoV-2 N protein. This cell line is the basis for the establishment of a cell-based screening assay using phase separation as a readout.\n<\/span><button class=\"readMoreBtn\">Read more<\/button>\n<\/div>\n\n<b>Partner:<\/b>\nAG L\u00e4ngst, Fraunhoferinstitut (Germany)\nMolecular Microbiology (Virology), Institute of Medical Microbiology and Hygiene, University of Regensburg (Germany)\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-1707a704 e-con-full e-flex e-con e-child\" data-id=\"1707a704\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-1d3223b0 elementor-widget elementor-widget-image\" data-id=\"1d3223b0\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"800\" height=\"233\" src=\"https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/02\/5.png\" class=\"attachment-large size-large wp-image-2350\" alt=\"\" srcset=\"https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/02\/5.png 800w, https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/02\/5-300x87.png 300w, https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/02\/5-768x224.png 768w\" sizes=\"(max-width: 800px) 100vw, 800px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-23a70a15 elementor-widget elementor-widget-image\" data-id=\"23a70a15\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"770\" height=\"600\" src=\"https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/02\/4.png\" class=\"attachment-large size-large wp-image-2351\" alt=\"\" srcset=\"https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/02\/4.png 770w, https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/02\/4-300x234.png 300w, https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/02\/4-768x598.png 768w\" sizes=\"(max-width: 770px) 100vw, 770px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-5d907efb e-flex e-con-boxed e-con e-parent\" data-id=\"5d907efb\" data-element_type=\"container\" id=\"tik\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-1d0ca5d1 e-con-full e-flex e-con e-child\" data-id=\"1d0ca5d1\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-622ae6ca elementor-widget elementor-widget-heading\" data-id=\"622ae6ca\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">TiKoCo<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6e578aa7 elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"6e578aa7\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"csc-header csc-header-n2\"><p><b>Funding:<\/b>\u00a0<b>Bavarian State Ministry of Science and Arts (StMWK) and National Research Network of the University Medicine (NUM; applied surveillance and testing; B-FAST)<br \/><\/b><strong>Full title:Tirschenreuth-Kohorte-Covid-19 study<\/strong><\/p><\/div><div class=\"csc-textpic csc-textpic-center csc-textpic-below\"><div class=\"csc-textpic-text\"><p>The Bavarian county of Tirschenreuth was one of the first \u201cCorona hot-spot\u201d areas in Germany, as it was hit by a severe outbreak of SARS-CoV-2 connected to a beer-festival in March 2020, which lead to a high incidence of (PCR-positive) cases and a remarkably high case fatality rate (CFR) of 11.5%. As it was unclear at this point of time if the CFR is based on insufficient identification of cases or on other unknown effects, the Tirschenreuth-Kohorte-Covid-19 (TiKoCo19) study was started to determine the actual seroprevalence in the county in collaboration with the FAU Erlangen and the LMU Munich.<\/p><div class=\"container\"><span class=\"moreText\"><span class=\"moreText\"><br \/>The study utilized a population based randomized sampling approach from government register, subsequently, 6608 residents of the Tirschenreuth area aged at least 14 years, were invited to participate in the study. Out of those, 4203 (63.6 %) participated in the study. In the following, blood samples were\/will be collected at a central blood drawing at three different time points.<\/span><\/span><p>The blood samples are analyzed for SARS-CoV-2 antibodies utilizing a variety of tests: the UR inhouse-ELISA, the commercially available Roche COBAS-Elecsys tests and further commercially available tests (e.g. by Shenzhen YHLO Biotech the market leader in Asia). On top, other tests as surrogate and wildtype neutralization assays, binding\/neutralization assays regarding the arising variants of concern are used. The aim of the project is to monitor SARS-CoV-2 seroprevalence, the surveillance detection ratio and infection fatality ratio as well as antibody stability, reinfections, vaccine effects and other possible effects\/correlations with e.g. age, profession or lifestyle factors.<\/p><p><b>Publications:<\/b><br \/><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34200766\/\">Wagner R, Peterhoff D, Beileke S, G\u00fcnther F, Berr M, Einhauser S, Sch\u00fctz A, Niller HH, Steininger P, Kn\u00f6ll A, Tenbusch M, Maier C, Korn K, Stark KJ, Gessner A, Burkhardt R, Kabesch M, Schedl H, K\u00fcchenhoff H, Pfahlberg AB, Heid IM, Gefeller O, \u00dcberla K.\u00a0<strong>Estimates and Determinants of SARS-Cov-2 Seroprevalence and Infection Fatality Ratio Using Latent Class Analysis: The Population-Based Tirschenreuth Study in the Hardest-Hit German County in Spring 2020.<\/strong> Viruses. 2021 Jun 10;13(6):1118.<\/a><\/p><p><a class=\"external-link-new-window\" title=\"Opens external link in new window\" href=\"https:\/\/www.mdpi.com\/2075-4418\/11\/10\/1843\" target=\"_blank\" rel=\"noopener\">Einhauser S, Peterhoff D, Niller HH, Beileke S, G\u00fcnther F, Steininger P, Burkhardt R, Heid IM, Pfahlberg AB, \u00dcberla K, et al.\u00a0<strong>Spectrum Bias and Individual Strengths of SARS-CoV-2 Serological Tests\u2014A Population-Based Evaluation.<\/strong>\u00a0Diagnostics. 2021; 11(10):1843.<\/a><\/p><p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35214782\/\">Peterhoff D, Einhauser S, Beileke S, Niller HH, G\u00fcnther F, Schachtner M, Asbach B, Steininger P, Tenbusch M, Peter AS, Gessner A, Burkhardt R, Heid IM, Wagner R, \u00dcberla K.\u00a0<strong>Comparative Immunogenicity of COVID-19 Vaccines in a Population-Based Cohort Study with SARS-CoV-2-Infected and Uninfected Participants.<\/strong>\u00a0Vaccines (Basel). 2022 Feb 18;10(2):324.<\/a><\/p><p><a href=\"https:\/\/www.mdpi.com\/1999-4915\/14\/6\/1168\">Einhauser S, Peterhoff D, Beileke S, G\u00fcnther F, Niller H-H, Steininger P, Kn\u00f6ll A, Korn K, Berr M, Sch\u00fctz A, et al.\u00a0<strong>Time Trend in SARS-CoV-2 Seropositivity, Surveillance Detection- and Infection Fatality Ratio until Spring 2021 in the Tirschenreuth County\u2014Results from a Population-Based Longitudinal Study in Germany.<\/strong>\u00a0Viruses. 2022; 14(6):1168.<\/a><\/p><br \/><button class=\"readMoreBtn\">Read more<\/button><\/div><p><b>Partners:<\/b><br \/>Molecular Microbiology (Virology), Institute of Medical Microbiology and Hygiene, University of Regensburg<br \/>Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg<br \/>Institute of Clinical and Molecular Virology, University Hospital Erlangen<br \/>Statistical Consulting Unit StaBLab, Department of Statistics, LMU Munich<br \/>Department of Genetic Epidemiology, University of Regensburg<br \/>Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg<br \/>University Children\u2019s Hospital Regensburg (KUNO) at the Hospital St. Hedwig of the Order of St. John, University of Regensburg<br \/>Bayerisches Rotes Kreuz, Kreisverband Tirschenreuth<br \/>Department of Medical Informatics, Biometry and Epidemiology, Friedrich-Alexander-Universit\u00e4t Erlangen-N\u00fcrnberg (FAU)<\/p><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-6a301465 e-con-full e-flex e-con e-child\" data-id=\"6a301465\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-44c382f1 elementor-widget elementor-widget-image\" data-id=\"44c382f1\" data-element_type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"800\" height=\"451\" src=\"https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/02\/2-3.png\" class=\"attachment-large size-large wp-image-2356\" alt=\"\" srcset=\"https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/02\/2-3.png 800w, https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/02\/2-3-300x169.png 300w, https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/02\/2-3-768x433.png 768w\" sizes=\"(max-width: 800px) 100vw, 800px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-222d1659 e-flex e-con-boxed e-con e-parent\" data-id=\"222d1659\" data-element_type=\"container\" id=\"cov\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-a109fcc e-con-full e-flex e-con e-child\" data-id=\"a109fcc\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-627310c8 elementor-widget elementor-widget-heading\" data-id=\"627310c8\" data-element_type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">CoVaCo<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-69dcfccc elementor-widget elementor-widget-text-editor\" data-id=\"69dcfccc\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"csc-header csc-header-n2\">\n\n<strong>Full title: Course of COVID-19 in vaccinated and non-vaccinated people<\/strong>\n\n<\/div>\n<div class=\"csc-textpic-text\">\n<p class=\"bodytext\">The COVID-19 vaccines approved in Germany show a high effectiveness against laboratory-confirmed COVID-19 diseases. Although the vaccines are highly effective in the pivotal studies, it can be assumed that there will a significant number of breakthrough infections due to the large number of those who will be vaccinated in a short time and emerging new virus variants. \n<div class=\"container\">\n    <span class=\"moreText\">\nThe focus of the project is the clinical, immunological and virological investigation of SARS-CoV-2 infections in COVID-19 vaccinated people compared to unvaccinated people. For this purpose, a multi-center prospective cohort study in people with newly diagnosed SARS-CoV- 2 infections is planned.<\/p>\n<\/span>\n<button class=\"readMoreBtn\">Read more<\/button>\n<\/div>\n\n<b>Project partners:\n<\/b>University Hospital Erlangen (Germany) \u2013 study coordinator\nMolecular Microbiology (Virology), Institute of Medical Microbiology and Hygiene, University of Regensburg (Germany)\nUniversity Hospital Augsburg (Germany)\nHospital of the University of Munich (LMU; Germany)\nKlinikum rechts der Isar of the Technical University of Munich (TUM; Germany)\nUniversity Hospital W\u00fcrzburg (Germany)\n\n<b>Further information:<\/b>\n<a class=\"external-link-new-window\" title=\"Opens external link in new window\" href=\"https:\/\/www.virologie.uk-erlangen.de\/covako\/\" target=\"_blank\" rel=\"noopener\">https:\/\/www.virologie.uk-erlangen.de\/covako\/<\/a>\n<a href=\"https:\/\/wagner-lab.de\/?p=106\">Our press release on the CoVaCo project<\/a>\n\n<\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-66649c13 e-con-full e-flex e-con e-child\" data-id=\"66649c13\" data-element_type=\"container\">\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>HIVacToGC Funding: The Federal Ministry of Education and Research (BMBF) Title: HIV Vaccine Targeting via DNA Origami Nanoparticles to lymph nodes to promote Germinal Center formation HIV has so far defied all attempts to develop an effective vaccine against it. Nine efficacy trials testing several vaccine candidates have been conducted in the last 25 years, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-3074","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Projects new - Wagner Lab<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/wagner-lab.de\/?page_id=3074\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Projects new - Wagner Lab\" \/>\n<meta property=\"og:description\" content=\"HIVacToGC Funding: The Federal Ministry of Education and Research (BMBF) Title: HIV Vaccine Targeting via DNA Origami Nanoparticles to lymph nodes to promote Germinal Center formation HIV has so far defied all attempts to develop an effective vaccine against it. Nine efficacy trials testing several vaccine candidates have been conducted in the last 25 years, [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/wagner-lab.de\/?page_id=3074\" \/>\n<meta property=\"og:site_name\" content=\"Wagner Lab\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-28T11:36:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/01\/cropped-hivactogc4.gif\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"17 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/wagner-lab.de\/?page_id=3074\",\"url\":\"https:\/\/wagner-lab.de\/?page_id=3074\",\"name\":\"Projects new - Wagner Lab\",\"isPartOf\":{\"@id\":\"https:\/\/wagner-lab.de\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/wagner-lab.de\/?page_id=3074#primaryimage\"},\"image\":{\"@id\":\"https:\/\/wagner-lab.de\/?page_id=3074#primaryimage\"},\"thumbnailUrl\":\"https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/01\/cropped-hivactogc4.gif\",\"datePublished\":\"2024-05-02T11:45:45+00:00\",\"dateModified\":\"2024-10-28T11:36:29+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/wagner-lab.de\/?page_id=3074#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/wagner-lab.de\/?page_id=3074\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/wagner-lab.de\/?page_id=3074#primaryimage\",\"url\":\"https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/01\/cropped-hivactogc4.gif\",\"contentUrl\":\"https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/01\/cropped-hivactogc4.gif\",\"width\":600,\"height\":172},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/wagner-lab.de\/?page_id=3074#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/wagner-lab.de\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Projects new\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/wagner-lab.de\/#website\",\"url\":\"https:\/\/wagner-lab.de\/\",\"name\":\"Wagner Lab\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/wagner-lab.de\/#organization\"},\"alternateName\":\"AG Wagner - Molecular virology - Regensburg\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/wagner-lab.de\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/wagner-lab.de\/#organization\",\"name\":\"Wagner Lab\",\"alternateName\":\"AG Prof. Ralf Wagner\",\"url\":\"https:\/\/wagner-lab.de\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/wagner-lab.de\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/wagner-lab.de\/wp-content\/uploads\/2023\/09\/wagnerLogo.jpeg\",\"contentUrl\":\"https:\/\/wagner-lab.de\/wp-content\/uploads\/2023\/09\/wagnerLogo.jpeg\",\"width\":193,\"height\":160,\"caption\":\"Wagner Lab\"},\"image\":{\"@id\":\"https:\/\/wagner-lab.de\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Projects new - Wagner Lab","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/wagner-lab.de\/?page_id=3074","og_locale":"en_GB","og_type":"article","og_title":"Projects new - Wagner Lab","og_description":"HIVacToGC Funding: The Federal Ministry of Education and Research (BMBF) Title: HIV Vaccine Targeting via DNA Origami Nanoparticles to lymph nodes to promote Germinal Center formation HIV has so far defied all attempts to develop an effective vaccine against it. Nine efficacy trials testing several vaccine candidates have been conducted in the last 25 years, [&hellip;]","og_url":"https:\/\/wagner-lab.de\/?page_id=3074","og_site_name":"Wagner Lab","article_modified_time":"2024-10-28T11:36:29+00:00","og_image":[{"url":"https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/01\/cropped-hivactogc4.gif"}],"twitter_card":"summary_large_image","twitter_misc":{"Estimated reading time":"17 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/wagner-lab.de\/?page_id=3074","url":"https:\/\/wagner-lab.de\/?page_id=3074","name":"Projects new - Wagner Lab","isPartOf":{"@id":"https:\/\/wagner-lab.de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/wagner-lab.de\/?page_id=3074#primaryimage"},"image":{"@id":"https:\/\/wagner-lab.de\/?page_id=3074#primaryimage"},"thumbnailUrl":"https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/01\/cropped-hivactogc4.gif","datePublished":"2024-05-02T11:45:45+00:00","dateModified":"2024-10-28T11:36:29+00:00","breadcrumb":{"@id":"https:\/\/wagner-lab.de\/?page_id=3074#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/wagner-lab.de\/?page_id=3074"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/wagner-lab.de\/?page_id=3074#primaryimage","url":"https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/01\/cropped-hivactogc4.gif","contentUrl":"https:\/\/wagner-lab.de\/wp-content\/uploads\/2024\/01\/cropped-hivactogc4.gif","width":600,"height":172},{"@type":"BreadcrumbList","@id":"https:\/\/wagner-lab.de\/?page_id=3074#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/wagner-lab.de\/"},{"@type":"ListItem","position":2,"name":"Projects new"}]},{"@type":"WebSite","@id":"https:\/\/wagner-lab.de\/#website","url":"https:\/\/wagner-lab.de\/","name":"Wagner Lab","description":"","publisher":{"@id":"https:\/\/wagner-lab.de\/#organization"},"alternateName":"AG Wagner - Molecular virology - Regensburg","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/wagner-lab.de\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/wagner-lab.de\/#organization","name":"Wagner Lab","alternateName":"AG Prof. Ralf Wagner","url":"https:\/\/wagner-lab.de\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/wagner-lab.de\/#\/schema\/logo\/image\/","url":"https:\/\/wagner-lab.de\/wp-content\/uploads\/2023\/09\/wagnerLogo.jpeg","contentUrl":"https:\/\/wagner-lab.de\/wp-content\/uploads\/2023\/09\/wagnerLogo.jpeg","width":193,"height":160,"caption":"Wagner Lab"},"image":{"@id":"https:\/\/wagner-lab.de\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/wagner-lab.de\/index.php?rest_route=\/wp\/v2\/pages\/3074","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wagner-lab.de\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/wagner-lab.de\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/wagner-lab.de\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/wagner-lab.de\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3074"}],"version-history":[{"count":143,"href":"https:\/\/wagner-lab.de\/index.php?rest_route=\/wp\/v2\/pages\/3074\/revisions"}],"predecessor-version":[{"id":3637,"href":"https:\/\/wagner-lab.de\/index.php?rest_route=\/wp\/v2\/pages\/3074\/revisions\/3637"}],"wp:attachment":[{"href":"https:\/\/wagner-lab.de\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3074"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}